Comparing the effect of 5% minoxidil and platelet-rich plasma combination with 5% minoxidil solution in androgenetic alopecia.

The aim of this study is to compare the efficacy of combined therapy with minoxidil and platelet-rich plasma (PRP) versus conventional minoxidil monotherapy in patients with androgenetic alopecia referred to Al-Zahra Hospital in Isfahan

This study is a randomized, two-arm, parallel-group, superiority, single-center clinical trial. Eligible patients were randomly allocated into either a combined treatment group (minoxidil + PRP) or a conventional treatment group (minoxidil alone) using a random number table. The sample size was determined based on the study inclusion and exclusion criteria, and outcome assessments were performed uniformly in both groups.

The study isconducted at Al-Zahra Hospital in Isfahan, in the dermatology outpatient clinic. Eligible patients are enrolled after obtaining informed consent and are randomly assigned to one of the two treatment groups. All treatment procedures and follow-up assessments are performed under the supervision of a dermatologist.

Patient consent Diagnosis confirmed by a specialist physician Age between 18 and 45 years No pharmacological treatment for alopecia within the past 6 months No history of cardiovascular disease and no use of antihypertensive medications No other types of alopecia or any systemic dermatologic disease No pregnancy, breastfeeding, or menopause in female participants

The intervention group consists of patients with androgenetic alopecia who receive combined treatment with topical minoxidil and platelet-rich plasma (PRP) injections according to the study protocol

hair density, hair thickness, patient satisfaction

Eligible patients meeting the inclusion criteria will be randomly allocated into two intervention groups using a random number table before initiation of treatment: Group 1: Combined therapy with PRP + 5% minoxidil Group 2: Monotherapy with 5% minoxidil Participants will remain unaware of their group assignment until the start of the intervention, ensuring initial patient blinding until treatment commencement. Allocation will be performed at a 1:1 ratio without stratification, with each patient having an equal probability of assignment to either group. Note: Given the nature of the intervention (PRP injection), complete patient blinding throughout the study is not feasible. However, outcome assessment (trichoscopy and photography) will be performed by an evaluator blinded to group allocation to minimize bias.